Article

Urodynamic system measures urethral function

Gynecare, a division of Ethicon, Inc., offers the Gynecare Monitorr urodynamicmeasurement system, featuring a new type of urethral pressure measurementfor stress incontinence-urethral retro-resistance pressure.

Related Videos
Wayne Kuang, MD, answers a question during a Zoom video interview
1 expert is featured in this series.
Raveen Syan, MD, FPMRS, answers a question during a Zoom video interview
Mohamad Baker Berjaoui, MD, answers a question during a Zoom video interview
Related Content
FDA reports Urgent Field Safety Notice on mini PCNL sheath
December 20th 2024

FDA reports Urgent Field Safety Notice on mini PCNL sheath

Hannah Clarke
The alert was issued to clarify that the devices should not be used for suction and irrigation.
Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults
November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD
Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.
Investigators identify potential dual targets in prostate cancer
December 20th 2024

Investigators identify potential dual targets in prostate cancer

Hannah Clarke
“Our findings highlight the coordinated interplay between GCN2 and p53 regulation during nutrient stress and provide insight into how they could be targeted in developing new therapeutic strategies for [prostate cancer]," write the authors.
Former MLB player Dave Winfield shares lessons from baseball, philanthropy
November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff
In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.
FDA greenlights phase 1/2 trial of gene editing therapy for primary hyperoxaluria 1
December 19th 2024

FDA greenlights phase 1/2 trial of gene editing therapy for primary hyperoxaluria 1

Hannah Clarke
The redePHine trial is expected to launch in the first half of 2025.
NCCN reaffirms Prolaris’ prognostic value in prostate cancer
December 18th 2024

NCCN reaffirms Prolaris’ prognostic value in prostate cancer

Hannah Clarke
The inclusion of the test is supported by more than 25 studies demonstrating its clinical utility, including 2 studies published earlier this year.
© 2024 MJH Life Sciences

All rights reserved.